Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Company Overview

Aldeyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage.

Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.

Key Stats

• Today's Range: $5.36 to $5.71
• 50-Day Range: $4.90 to $5.89
• 52-Week Range: $1.14 to $7.20
• Volume: 980,965 shs
• Average Volume: 748,037 shs
• Market Capitalization: $322.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Hold

Aldeyra Therapeutics Stock Analysis - MarketRank™

Aldeyra Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 631st out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Aldeyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Aldeyra Therapeutics has a consensus price target of $9.50, representing about 76.3% upside from its current price of $5.39.

Amount of Analyst Coverage

Aldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aldeyra Therapeutics is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aldeyra Therapeutics is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aldeyra Therapeutics has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.98% of the outstanding shares of Aldeyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently increased by 1.70%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aldeyra Therapeutics does not currently pay a dividend.

Dividend Growth

Aldeyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.98% of the outstanding shares of Aldeyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently increased by 1.70%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.62

News Sentiment

Aldeyra Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aldeyra Therapeutics this week, compared to 3 articles on an average week.

Search Interest

8 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

2 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aldeyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $113,676.00 in company stock.

Percentage Held by Insiders

Only 9.60% of the stock of Aldeyra Therapeutics is held by insiders.

Percentage Held by Institutions

59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALDX Stock Analysis - Frequently Asked Questions

How have ALDX shares performed this year?

Aldeyra Therapeutics' stock was trading at $4.99 at the start of the year. Since then, ALDX stock has increased by 8.0% and is now trading at $5.39.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) posted its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05.

Who are Aldeyra Therapeutics' major shareholders?

Top institutional investors of Aldeyra Therapeutics include Voya Investment Management LLC (0.02%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Stephen Machatha, Bruce Greenberg and Nancy Miller-Rich.
View institutional ownership trends.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/11/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALDX
• CIK: 1341235
• Web: www.ampliphibio.com
• Phone: 781-761-4904
• Fax: 781-270-0630
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Aldeyra Therapeutics: $9.50
• High Price Target: $10.00
• Low Price Target: $9.00
• Potential Upside/Downside: +76.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.63%
• Return on Assets: -50.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.86
• Quick Ratio: 2.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.19 per share
• Price / Book: 4.53

Miscellaneous

• Outstanding Shares: 59,900,000
• Free Float: 54,146,000
• Market Cap: $322.86 million
• Optionable: Optionable
• Beta: 0.83